ATAI Life's Schizophrenia Candidate Shows Promising Action In Mid-Stage Study

  • ATAI Life Sciences NV ATAI announced interim data from the first 8-patient cohort of its Phase 2a trial of RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS).
  • Related Link: Peter Thiel Backed Atai Life Launches New Mental Health Disorders-Focused Company. 
  • Data demonstrated potential pro-cognitive effects of RL-007, a cholinergic, glutamatergic, and GABA type B receptor modulator. 
  • After this early data, ATAI will commit additional financial resources for the accelerated development of RL-007.
  • The interim Phase 2a readout reported promising assessments from two quantitative biomarkers, qEEG (quantitative electroencephalogram) and ERP (evoked-response potential), and indicated changes consistent with improved cognition. 
  • Full results of the current Phase 2a trial are expected by the end of 2021.
  • Related: Teva Reports Encouraging Data From Late-Stage Schizophrenia Trial.
  • Price Action: ATAI shares closed 6.37% higher at $15.52 on Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsPhase 2 TrialSchizophrenia
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!